Medically reviewed by Marla Anderson, MD Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which ...

The initial symptoms of GVHD typically appear on the skin, often because GVHD first damages and causes inflammation in skin cells, says Azra Borogovac, MD, a hematologist at City of Hope in Irvine ...

The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...

3 Chronic GvHD also tends to start with a burning rash on the same parts of the body, although it can be more severe and ...

GvHD causes life-threatening immune system reactions in the skin, gastrointestinal (GI ... Many differences exist between human and mouse immune systems and their MSCs. Instead, he says, more ...

John Levine, M.D., a graft-versus-host-disease expert at the Icahn School of Medicine at Mount Sinai in New York, makes a ...

The graft is grown from mouse stem cells engineered by CRISPR to produce the GLP ... this would be “like another way of taking a drug orally—in this case it’s on your skin,” he says. The stem cells ...

the potential for GvHD is greatly reduced. The dual effect has been demonstrated in mouse models of allogeneic HSCT, and mocravimod has been found to be safe and well-tolerated in human safety ...

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit ... scleroderma that causes skin hardening and organ damage.

Incyte’s JAK1 inhibitor itacitinib has failed a key trial in graft-versus-host disease (GVHD), marking another ... with Keytruda alone in a late-stage skin cancer study. Reduction in force ...